JACOB REEDY: Open Payments
NPI 1114530565 · HAYDEN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$485 in 24 payments from 9 companies in 2025. Trend: 2023 $443 · 2024 $615 · 2025 $485
Food & beverage: $485
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $149 |
| GlaxoSmithKline, LLC. | 4 | $89 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $57 |
| Vifor Pharma, Inc. | 3 | $53 |
| Ardelyx, Inc. | 3 | $51 |
| Amgen Inc. | 1 | $31 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| AKEBIA THERAPEUTICS INC | 1 | $14 |
Products named: BENLYSTA, Vanrafia, Kerendia, Veltassa, IBSRELA, KRYSTEXXA, Fabhalta, TARPEYO.
Industry payments across ID — which companies pay providers there.
